A randomized double-blind, double-dummy, multicenter trial of azasetron versus ondansetron to evaluate efficacy and safety in the prevention of delayed nausea and vomiting induced by chemotherapy

Cancer Research and Treatment

Volumn 46, Issue 1, 2014, Pages 19-26

  Lee, Hee Yeon ^a   Kim, Hoon Kyo ^a   Lee, Kyung Hee ^b   Kim, Bong Seog ^c   Song, Hong Suk ^d   Yang, Sung Hyun ^e   Kim, Joon Hee ^f   Kim, Yeul Hong ^g   Kim, Jong Gwang ^h   Kim, Sang We ⁱ   Kim, Dong Wan ^j   Kim, Si Young ^k   Park, Hee Sook ^l  

^a The Catholic University of Korea   (South Korea)

^b Yeungnam University Hospital   (South Korea)

^c Seoul Veterans Hospital   (South Korea)

^d Dongsan Medical Center   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g College of Medicine   (South Korea)

^h Kyungpook National University Hospital   (South Korea)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j Seoul National University Hospital   (South Korea)

^k Kyung Hee University College of Medicine   (South Korea)

^l Soonchunhyang University College of Medicine   (South Korea)

more..

Author keywords

Antineoplastic agents; Azasetron; Ondansetron; Serotonin antagonists; Vomiting; Vomiting chemically induced; Vomiting prevention and control

Indexed keywords

EID: 84893919170     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2014.46.1.19     Document Type: Article

References (25)

1. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13:219-27.
2. Cheirsilpa A, Sinthusake T, Songsakkaesorn A, Visawaprasit S, Chulaka K, Changkuingdee N. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin-based chemotherapy: a randomized controlled trial. Jpn J Clin Oncol. 2005;35:695-9.
3. Yun MJ, Kim YH, Kim AR. Comparison of azasetron and ondansetron for preventing postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery. Yonsei Med J. 2010;51:88-92.
4. Navari RM. Pathogenesis-based treatment of chemotherapyinduced nausea and vomiting: two new agents. J Support Oncol. 2003;1:89-103.
5. Sakamori M, Takehara S, Setoguchi M. High affinity binding of Y-25130 for serotonin 3 receptor. Nihon Yakurigaku Zasshi. 1992;100:137-42.
6. Tsukagoshi S. Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist. Gan To Kagaku Ryoho. 1999;26:1001-8.
7. Hayakawa T, Sato M, Konaka M, Makino A, Hirohata T, Totsu S, et al. Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients. Gan To Kagaku Ryoho. 2006;33:633-8.
8. Kimura E, Niimi S, Watanabe A, Tanaka T. Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho. 1997;24:855-9.
9. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-9.
10. Ishiwata K, Ishii K, Ishii S, Senda M. Synthesis of 5-HT3 receptor antagonists, [11C] Y-25130 and [11C] YM060. Appl Radiat Isot. 1995;46:907-10.
11. Yang SH, Lee MG. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. Biopharm Drug Dispos. 2008;29:414-26.
12. Simpson KH, Murphy P, Colthup PV, Whelan P. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology (Berl). 1992;109:497-8.
13. Rudd JA, Naylor RJ. Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology. 1994;33:1607-8.
14. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23:1289-94.
15. Haga K, Inaba K, Shoji H, Morimoto Y, Fukuda T, Setoguchi M. The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. Jpn J Pharmacol. 1993;63:377-83.
16. Yamada Y, Fujita M, Okuyama K, Takayanagi R, Ozeki T, Yokoyama H, et al. Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin. Yakugaku Zasshi. 2007;127: 353-7.
17. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol. 1995;13:1036-43.
18. Tsukuda M, Mochimatsu I, Furukawa M, Kohno H, Kawai S, Enomoto H, et al. A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin. Gan To Kagaku Ryoho. 1995;22:1959-67.
19. Kimura E, Niimi S, Watanabe A, Akiyama M, Tanaka T. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho. 1996;23:477- 81.
20. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995;13:1242-8.
21. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:1174-8.
22. Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin JP, et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997;8:181-5.
23. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The Italian Group for Antiemetic Research. N Engl J Med. 2000;342:1554-9.
24. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60:533-46.
25. Huskey SE, Dean BJ, Bakhtiar R, Sanchez RI, Tattersall FD, Rycroft W, et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos. 2003;31:785-91.